

Gastroenterology

Volume 170 / Issue 2

February 2026

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER



Shame in Bowel Disorders of Gut-Brain Interaction. See article by Trindade, et al, page 353 for additional information.

COMMENTARIES

- 233** **Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action**
S.-H. Lee, E. W. Lopes, H. Khalili, K. Croitoru, J.-F. Colombel, and I. Peter, on behalf of the 2025 PROMISE Workshop participants

- 240** **Mass Screening of Celiac Disease: A Crossing Point Between Secondary and Primary Prevention?**
M. G. Stahl, M. M. Leonard, E. Liu, M. I. Pinto-Sanchez, G. Lack, and C. Catassi

DIVERSITY, EQUITY, AND INCLUSION IN GI

- 246** **Knowledge, Attitudes, and Environment Related to Gastroenterology and Hepatology Care for Sexual and Gender Minorities**
T.-H. Lee, N. Duong, D. A. Simonetto, Intersociety Diversity Group Representatives, S. Paul, and K. L. Newman

MENTORING, EDUCATION, AND TRAINING CORNER

- 252** **Building a Culture of Excellence in Your Gastroenterology Fellowship: Creating a High VALUE Program**
S. M. Ordway, K. E. Driggers, P. E. Young, and J. G. McCarthy

EDITORIALS

- 256** **Molecular Early Detection for Pancreatic Cancer in High-Risk Individuals: Are We Sure Yet?**
J. B. Kisiel, D. W. Mahoney, and S. Majumder
See Lucas AL et al on page 375.

V Video

CGH Related article in CGH

Hot Papers From New Investigators

CME CME quiz

E Editorial accompanies this article

www Additional online content available

COV Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2026 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 257 Refining Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease: Moving Beyond Histology With Individualized Noninvasive Predictive Models for Clinical Events**
L. Castera
See Aceituno L et al on page 385.

GASTRO CURBSIDE CONSULT

- 260 An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair**
T.-W. Lou, T.-Y. Ren, and J.-G. Fan

- 264 A Patient With Liver Injury, Portal Hypertension, Anemia, and Peripheral Neuropathy**
L. Li, Y. Wang, and B. Deng

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 268 The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective**
F. Wang, K. Görgülü, H. Algül, and L.-H. Hu

ORIGINAL RESEARCH

Full Reports

Esophagus

- 287 Histologic Response Is Associated With Improved Esophageal Distensibility and Symptom Burden in Pediatric Eosinophilic Esophagitis**
K. V. Kennedy, C. Burger, Z. Pan, C. N. Umeweni, M. Alston, A. J. Benitez, G. T. Furuta, M. Mahon, M. A. Ruffner, L. Quinn, A. B. Muir, and C. Menard-Katcher

Esophageal distensibility was characterized over time in pediatric patients with eosinophilic esophagitis. Histologic response was found to be associated with improved distensibility, and baseline distensibility may help predict clinical symptoms and fibrostenotic progression.

GI Cancer

- 298 Intestinal *LKB1* Loss Drives a Premalignant Program Along the Serrated Cancer Pathway**
S. F. Plugge, H. Ma, J. Y. van der Vaart, J. Sprangers, F. H. M. Morsink, D. Xanthakis, C. Jamieson, K. B. W. Stroot, A. R. Keijzer, T. Margaritis, T. Candelli, R. Straver, J. de Ridder, F. C. P. Holstege, W. W. J. de Leng, G. J. A. Offerhaus, A. Merenda, and M. M. Maurice

Lkb1 loss in intestinal organoids leads to alterations in secretory cell morphology and a chronic state of tissue repair, which promotes cancer predisposition, particularly in the serrated pathway.

- 315 Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer**
H. Köse, C. Schneeweis, P. Putze, C. T. Contreras, L. Ferreira, L. Witte, I. Deidda, F. Herzberg, S. Ebert, J. Jakubik, L. Moldaner, J. Todorovic, I. Träger, C. Zang, U. M. Demel, E. Hessmann, M. Kirchner, S. Rhein, J. Hoffmann, Z. Tatarova, M. Ghadimi, D. Saur, K. Kappert, P. Mertins, G. Schneider, U. Keller, and M. Wirth

Blocking phosphatidylinositol-3-kinase and small ubiquitin-like modifier pathways together kills pancreatic cancer cells and leads to an immune-assisted antitumor response, offering a new treatment approach for this difficult-to-treat cancer.

- 330** **An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study**
A. Mannucci, F. Balaguer, Y. Yamada, T. Nagasaka, Y. Toiyama, Y. Okugawa, M. Martí-Gallostra, M. Jiménez-Toscano, R. Vidal-Tocino, F. Jiménez, J. Perea, E. Quintero, C. Richard Boland, G. M. Cavestro, and A. Goel, on behalf of the SECOC-ENCODER Collaborators

In order to combat the increasing incidence of colorectal cancer in young adults, the ENCODER study developed, trained, and independently tested a highly sensitive and specific noninvasive, patient-friendly, blood-based test for the detection and prevention of this disease.

- 344** **The Disease Burden of *Helicobacter pylori* Beyond Gastric Cancer: Quantifying the Forgotten Potential Benefits of Mass Eradication**
D. T. Mülder, J. F. O'Mahony, N. Kapteijn, T. K. Bric, J. Honing, M. C. W. Spaander, Y.-C. Lee, B. Tepes, J. Bornschein, M. Leja, and I. Lansdorp-Vogelaar

Treatment of the bacterial infection *Helicobacter pylori* is often aimed at preventing gastric cancer, but also prevents other diseases, such as ulcers. Although these diseases are rarely lethal, they often cause discomfort and, therefore, should be considered in the decision whether to screen-and-treat for *Helicobacter pylori*.

Functional GI Disease

- 353** **Implications of Shame for Patient-Reported Outcomes in Bowel Disorders of Gut-Brain Interaction**

I. A. Trindade, A. Blomsten, S. Nybacka, E. Colomier, R. Sandberg, Å. Frändemark, H. Törnblom, and M. Simrén

Compared with healthy controls, individuals with bowel disorders of gut-brain interaction experience higher levels of shame, which is associated with psychological distress, impairment in daily activities, and lower quality of life.

- 365** **The Prevalence and Burden of Avoidant/Restrictive Food Intake Disorder Symptoms in Adults With Disorders of Gut-Brain Interaction: A Population-Based Study**

R. Flack, G. Brownlow, H. Burton-Murray, O. Palsson, and I. Aziz

Individuals with disorders of gut-brain interaction, such as irritable bowel syndrome or functional dyspepsia, frequently show signs of avoidant/restrictive food intake disorder. Healthcare professionals (eg, doctors, dietitians, and psychologists) should regularly assess eating patterns in such patients and collaborate to improve outcomes.

Pancreas

- 375** **Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma**

A. L. Lucas, D. M. Simeone, B. W. Katona, S. Paiella, G. Zogopoulos, R. C. Sears, E. M. Grindedal, R. C. Wadlow, E. Borazanci, O. K. Gordon, F. Kastrinos, J. G. Trevino, S. S. Kupfer, W. G. Park, J. N. Everett, N. M. Kureshi, G. DeMuth, L. Ford, T. King, N. A. Palma, and R. E. Brand

See editorial on page 256.

A panel of 5 biomarkers performed well at detecting early-stage pancreatic cancer in individuals with stage I and II pancreatic tumors and in cancer-free individuals at high risk of developing the disease.

Hepatobiliary

- 385** **The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease**

L. Aceituno, J. Bañares, M. Pons, J. Rivera-Esteban, C. Sabiote, C. Cammà, G. Ciancimino, G. Pennisi, A. Tulone, M. M. Ma, X. Liu, T. R. Watkins, A. N. Billin, S. Petta, J. M. Pericàs, J. G. Abraldes, and J. Genesca

See editorial on page 257.

By using a combination of simple laboratory and imaging parameters in metabolic fatty liver disease, it is easier and more accurate to explain to the patient what could be the outcome of the disease compared with examining a liver sample obtained by liver puncture.

RESEARCH LETTERS

- 395 **Magnitude and Characteristics of National Institute of Diabetes and Digestive and Kidney Diseases Grant Rescissions**
W. Haque, E. Haque, I. Rana, M. Espinoza, and D. Hsiehchen
- 398 **Addressing Colonoscopy Burden Due to Artificial Intelligence Devices for Polyp Detection**
Y. Mori, P. Wang, S. Kamba, L. Liu, P. D. Siersema, C. Hassan, and The Co-AID Study Group
- 401 **Esophageal Hypervigilance and Anxiety Predict Post-Treatment Outcomes in Achalasia**
L. Guadagnoli, D. A. Carlson, E. Goudie, and J. E. Pandolfino
- 404 **Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial**
L. M. A. van Lierop, M. J. C. Devillers, C. J. van der Woude, F. Hoentjen, A. C. de Vries, and LADI LTFU Study Group

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e9 **CME Exam 1: The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective**

CLINICAL PRACTICE UPDATES

- 408 **AGA Clinical Practice Update on Inpatient Management of Adults With Inflammatory Bowel Disease: Expert Review**
S. Cohen-Mekelburg, J. G. Hashash, E. V. Loftus Jr, and D. T. Rubin

GASTRO DIGEST

- 418 **Structured Exercise for Patients With Colon Cancer**
V. Sallinen
- 418 **Beneficial Effects of Physical Exercise on Anticancer Immunity Are Mediated by Gut Microbiome Metabolites**
A. S. Carlà and G. Ianaro
- 419 **Semaglutide in MASH: A Promising Step Forward With Room for Improvement**
S. Lens

CORRESPONDENCE

- 421 **Revisiting Gender Differences in Gastric Cancer Prevention With *Helicobacter pylori* Eradication Therapy**
K. Li, A. Lin, and P. Luo
- 422 **Methodological Considerations in Evaluating the Preventive Effect of *Helicobacter pylori* Eradication on Gastric Cancer Incidence and Mortality**
H. Chen, S. Liu, H. Zhi, J. Zheng, and X. Chen
- 423 **Reassessing the Observational Evidence for *Helicobacter pylori* Eradication and Gastric Cancer Prevention**
J. Lu and L. Huang
- 424 **Comments on "Preventive Effect of *Helicobacter pylori* Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study"**
X. Tang, J. Zhao, J. Hu, L. Zhang, and D. Ma
- 425 **Translating Population-Based Evidence on *Helicobacter pylori* Eradication Into Precision Surveillance Strategies**
Y. Shiratori, N. Ishii, and A. Kalloo

- 426 Reevaluating the GRAVITI Trial of Subcutaneous Guselkumab for Crohn's Disease**
J. Liu, Y. Shi, and Y. Yang
- 427 Subcutaneous Interleukin 23 Blockade as a Patient-Centered Strategy in Crohn's Disease**
J. Xu, Y. Gao, and Y. Zhang
- 427 GRAVITI Study on Guselkumab's Efficacy and Safety for Moderate to Severe Crohn's Disease**
H. Wang, K. Xue, Y. Kong, and X. Shen
- 428 Advancing Patient Care With the GRAVITI Trial**
Y. Cai and L. Liu
- 429 Revolutionizing Gastroenterology With Artificial Intelligence: Clinical Insights and Challenges**
Y. Miao, Y. Wei, and A. Shang
- 430 Human-AI Interaction and Global Disparities in the Clinical Implementation of Medical AI**
P. Hu, C. Zheng, and X. Shao
- 431 Assessment of Methods in AOH1996 Studies for Pancreatic Ductal Adenocarcinoma Therapy**
G. Li
- 432 Reply**
F. Meng and M. Raoof
- 433 Critical Role of Fucosyltransferase VII in Glycosylation-Dependent Regulatory T-Cell Function in Inflammatory Bowel Disease**
Q. Fan and M. Li
- 434 Reply**
G. Tan and T. Ben
- 435 Is It Just About How Much You Drink? The Overlooked Role of Drinking Patterns in Fatty Liver Disease**
S. Dai, Z. Fei, L. Sun, and P. Wang
- 436 Reply**
H. Xue, L. Wang, and C. Yu
- 437 Comments on "Coaching in Gastroenterology Training"**
W. Ahmad, S. Lewin, and P. Kathpalia
- 438 Reply**
I. Bhavsar-Burke, A. K. Miller Juve, and E. K. Boden
- 438 Mechanistic Gaps and Therapeutic Promise in MASH-ATM sEV Research**
Y. Fang, Y. Bian, and L. Zeng

- 439 Reply**
T. V. Rohm, K. Cunha e Rocha, and J. M. Olefsky

- 441 Corrigenda**

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

**Sample
mailing
label**

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001